Deutsche Märkte geschlossen

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
1.020,98-6,69 (-0,65%)
Ab 02:35PM EDT. Markt geöffnet.

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000


Leitende Angestellte

Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, CEO & Co-Chairman8,18MN/A1953
Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman7,76MN/A1960
Dr. Andrew J. Murphy Ph.D.Executive Vice President of Research1,68M21,37M1959
Mr. Daniel P. Van PlewExecutive VP and GM of Industrial Operations & Product Supply2,01M10,67M1973
Mr. Christopher R. Fenimore CPASenior VP of Finance & CFON/AN/A1971
Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsN/AN/AN/A
Mr. Bob McCowanSenior VP of IT & Chief Information OfficerN/AN/AN/A
Mr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisN/AN/AN/A
Mr. Joseph J. LaRosaExecutive VP, General Counsel & Secretary1,75M23,23M1959
Ms. Melissa LoznerSenior VP & Chief Compliance OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.


Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Corporate Governance

Regeneron Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 10. Die grundlegenden Scores sind Audit: 8, Vorstand: 10, Shareholderrechte: 10, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.